Environmental enrichment as a multisystem modulator of neurotransmitter function: mechanisms, plasticity, and therapeutic implications
- 1Department of Otolaryngology - Head and Neck Surgery, University of Wisconsin , , ,
- 2Department of Psychiatry, University of Münster , ,
Abstract
Environmental enrichment (EE) has emerged as a powerful non-pharmacological strategy for reshaping brain function through experience dependent plasticity. By integrating sensory, cognitive, motor, and social stimulation, EE provides a biologically relevant framework for understanding how external environments influence neurotransmitter systems that govern mood, cognition, stress adaptation, and neurodegeneration. In this review, we examined the effects of EE on major neurotransmitter pathways, including serotonergic, dopaminergic, glutamatergic, GABAergic, cholinergic, adrenergic, and histaminergic systems. We conducted a structured narrative search of PubMed, supplemented by Google Scholar reference list searching and informed by PRISMA reporting principles. The literature search covered studies published through 4 September 2026. The initial search, completed in February 2025, included 136 articles. A supplemental update screened 108 PubMed records and identified seven additional eligible primary studies, resulting in an updated evidence synthesis comprising 143 articles. Across predominantly preclinical studies, EE was consistently associated with enhanced neurogenesis, synaptic plasticity, stress resilience, and improved behavioral and cognitive outcomes, accompanied by neurotransmitter related changes across multiple brain systems. The most robust evidence supported modulation of serotonergic, dopaminergic, glutamatergic, and GABAergic pathways, whereas adrenergic and histaminergic effects were less well characterized and often indirect. Mechanistically, these effects converged on altered receptor and transporter expression, neurotrophic signaling, CREB dependent transcriptional regulation, and epigenetic remodeling. Collectively, the evidence positions EE as a multisystem regulator of neurotransmitter function with potential relevance to mood disorders, neuroinflammation, neurodegeneration, stroke, addiction, and cognitive decline. Nevertheless, the field remains limited by the predominance of animal data and by substantial heterogeneity in enrichment paradigms. Future translational and clinical studies are needed to define the most effective EE components, timing, and intensity for therapeutic application in humans.
Related
- The SCF/KIT signaling pathway in multisystem diseases: Mechanisms and therapeutic targeting
- Regional alignment with sex-typical brain architecture, maternal health and environmental enrichment predict psychiatric symptoms in early life
- Nail-Patella Syndrome in a 76-Year-Old Woman: Multisystem Phenotype, Diagnostic Delay, and Clinical Implications
- The Effects of Environmental Enrichment on the Behavior of Laboratory Zebrafish (Danio rerio).
- Environmental enrichment is associated with changes in the gut microbiome and resistome of captive pythons
BibTeX
@article{singhal2026environmental,
title = {{Environmental enrichment as a multisystem modulator of neurotransmitter function: mechanisms, plasticity, and therapeutic implications}},
author = {Gaurav Singhal and Bernhard T. Baune},
journal = {Frontiers in molecular neuroscience},
year = {2026},
month = oct,
doi = {10.3389/fnmol.2026.1927924},
url = {https://europepmc.org/article/PMC/PMC13720593},
note = {CC BY},
}
RIS
TY - JOUR
TI - Environmental enrichment as a multisystem modulator of neurotransmitter function: mechanisms, plasticity, and therapeutic implications
AU - Gaurav Singhal
AU - Bernhard T. Baune
PY - 2026
DA - 2026/10/16
JO - Frontiers in molecular neuroscience
DO - 10.3389/fnmol.2026.1927924
UR - https://europepmc.org/article/PMC/PMC13720593
AB - Environmental enrichment (EE) has emerged as a powerful non-pharmacological strategy for reshaping brain function through experience dependent plasticity. By integrating sensory, cognitive, motor, and social stimulation, EE provides a biologically relevant framework for understanding how external environments influence neurotransmitter systems that govern mood, cognition, stress adaptation, and neurodegeneration. In this review, we examined the effects of EE on major neurotransmitter pathways, including serotonergic, dopaminergic, glutamatergic, GABAergic, cholinergic, adrenergic, and histaminergic systems. We conducted a structured narrative search of PubMed, supplemented by Google Scholar reference list searching and informed by PRISMA reporting principles. The literature search covered studies published through 4 September 2026. The initial search, completed in February 2025, included 136 articles. A supplemental update screened 108 PubMed records and identified seven additional eligible primary studies, resulting in an updated evidence synthesis comprising 143 articles. Across predominantly preclinical studies, EE was consistently associated with enhanced neurogenesis, synaptic plasticity, stress resilience, and improved behavioral and cognitive outcomes, accompanied by neurotransmitter related changes across multiple brain systems. The most robust evidence supported modulation of serotonergic, dopaminergic, glutamatergic, and GABAergic pathways, whereas adrenergic and histaminergic effects were less well characterized and often indirect. Mechanistically, these effects converged on altered receptor and transporter expression, neurotrophic signaling, CREB dependent transcriptional regulation, and epigenetic remodeling. Collectively, the evidence positions EE as a multisystem regulator of neurotransmitter function with potential relevance to mood disorders, neuroinflammation, neurodegeneration, stroke, addiction, and cognitive decline. Nevertheless, the field remains limited by the predominance of animal data and by substantial heterogeneity in enrichment paradigms. Future translational and clinical studies are needed to define the most effective EE components, timing, and intensity for therapeutic application in humans.
SN - 1662-5099
ER -